Merck (MRK) stock fell 9.5% in the week ended November 20, 2026, slightly underperforming the S&P 500's 8.6% decline, after the company discontinued development of nemtabrutinib, an experimental blood cancer drug acquired through its $2.7 billion ArQule deal [1]. An independent review of a Phase 3 trial determined that the drug's benefits may not outweigh its risks [1]. Despite this setback, the impact on Merck's overall business appears limited, as nemtabrutinib represented a small loss relative to Keytruda's $31.7 billion in 2025 sales [1]. The discontinuation benefits competitor Eli Lilly (LLY), whose rival drug Jaypirca generated $228 million in third-quarter sales, up 59% [1].
Merck also achieved a significant legal victory when a German appeals court overturned a preliminary injunction that Halozyme Therapeutics (HALO) had won in December 2025 against under-the-skin Keytruda [1]. However, a separate Dutch ruling from October restricting the drug in eight European markets remains in effect [1]. The company's third-quarter financial performance showed resilience, with sales rising 5% to $18.1 billion, and Merck raised the low end of its 2026 sales guidance to a range of $66.8-$67.3 billion [1]. Additionally, the company increased its quarterly dividend to $0.88 from $0.85 [1].
Analysts maintain a constructive outlook despite the recent decline. Consensus normalized earnings per share is expected to fall to $2.79 in 2026 due to acquisition charges, but is projected to recover to $8.96 in 2027, returning to 2025 levels [1]. CFO Caroline Litchfield characterized Keytruda's U.S. patent loss in 2028 as "really more of a hill on the overall revenues of our company," a characterization with which analysts agree [1]. At approximately 16x forward earnings following the decline, Merck appears attractively valued compared to its five-year average of 14x [1]. The $162 consensus price target sits approximately 21% above the November 20 close of $133.72 [1], suggesting meaningful upside potential for investors.
CONCLUSION
Merck's 9.5% weekly decline appears overdone given the limited financial impact of the nemtabrutinib discontinuation and the company's strong underlying fundamentals, including a 5% sales increase and raised 2026 guidance. At 16x forward earnings with a $162 consensus price target implying 21% upside, the stock presents a potential buying opportunity for investors concerned about Keytruda's 2028 patent expiration.